BELLUS Health Inc.

Laval, Canada

BELLUS Health Inc.

Laval, Canada
SEARCH FILTERS
Time filter
Source Type

News Article | May 22, 2017
Site: www.businesswire.com

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and fiscal year ended March 31, 2017. Mr. Abhay Gandhi, Taro’s Interim CEO said, “As is commonly known, and as we have stated for quite some time, the entire generic sector, including Taro, is facing a challenging period. We continue to see a difficult generic pricing environment, particularly in the U.S., driven by intensified competition among manufacturers, new entrants to the market, buying consortium pressures, and higher ANDA approval rate from the FDA.” Mr. Gandhi continued, “Based on our well-balanced portfolio, the continuing focus on R&D investment, our healthy pipeline, and the Company’s strong balance sheet, we believe we are well positioned in our target markets.” The Company recently received approvals from the U.S. Food and Drug Administration (“FDA”) for four Abbreviated New Drug Applications (“ANDAs”): Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup 2 mg/5 mL, 30mg/5 mL, 10 mg/5 mL, Metronidazole Gel USP, 1%, Tazarotene Cream, 0.1% and Felbamate Tablets, 400 mg and 600 mg. The Company currently has a total of thirty-five ANDAs awaiting FDA approval, including 5 tentative approvals. On November 23, 2016, the Company announced that its’ Board of Directors approved a new $250 million share repurchase of ordinary shares. This authorization follows the successful completion of the previous $250 million share repurchase program on August 19, 2016; under which, the Company bought back 1,801,099 of its ordinary shares, of which, 1,733,760 shares were purchased subsequent to April 1, 2016. Under the November 2016 authorization, repurchases may be made from time to time at the Company’s discretion, based on ongoing assessments of the capital needs of the business, the market price of its stock, and general market conditions. No time period has been set for the repurchase program, and any such program may be suspended or discontinued at any time. The repurchase authorization enables the Company to purchase its ordinary shares from time to time through open market purchases, negotiated transactions or other means, including 10b5-1 trading plans in accordance with applicable securities laws or other restrictions. During the fourth quarter, the Company repurchased 207,503 shares at an average price of $103.99. During the year, the Company repurchased 2,252,725 shares between the two programs. On March 16, 2017, BELLUS Health Inc.(“BELLUS”) announced that it had entered into a share purchase agreement with Taro for the sale of BELLUS’ wholly-owned subsidiary Thallion Pharmaceuticals Inc. (“Thallion”), including all the rights to the drug candidate Shigamab™. Pursuant to the agreement, Taro is acquiring all issued and outstanding shares of Thallion for a potential total consideration of CAD $2.7 million. In addition, BELLUS will receive a portion of certain post-approval revenues related to the Shigamab™ program. Development and Commercialization license to sell and distribute Pliaglis® On April 25, 2017, Crescita Therapeutics Inc. (“Crescita”), announced it had entered into a development and commercialization license agreement with Taro, under which, Crescita has granted Taro an exclusive license to the rights to sell and distribute Pliaglis® in the U.S. market and for a second-generation enhanced version with patent pending. As previously announced, the Company will host an earnings call at 8:00 am EDT on Tuesday, May 23, 2017, where senior management will discuss the Company’s performance and answer questions from participants. This call will be accessible through an audio dial-in and a web-cast. Audio conference participants can dial-in on the numbers below: To participate in the audio call, please dial the numbers provided above five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. The transcript of the event will be available on the Company’s website at www.taro.com. An audio playback will be available for twenty four (24) days following the call. Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com. The unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments necessary to present fairly the financial condition and results of operations of the Company. The unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 20-F, as filed with the SEC. Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements that do not describe historical facts or that refer or relate to events or circumstances the Company “estimates,” “believes,” or “expects” to happen or similar language, and statements with respect to the Company’s financial performance, availability of financial information, and estimates of financial results and information for fiscal year 2018. Although the Company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained. Factors that could cause actual results to differ include general domestic and international economic conditions, industry and market conditions, changes in the Company's financial position, litigation brought by any party in any court in Israel, the United States, or any country in which Taro operates, regulatory and legislative actions in the countries in which Taro operates, and other risks detailed from time to time in the Company’s SEC reports, including its Annual Reports on Form 20-F. Forward-looking statements are applicable only as of the date on which they are made. The Company undertakes no obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.


Browse 19 Tables and 10 Figures, 10 Companies, spread across 82 pages available at http://www.reportsnreports.com/reports/983972-interstitial-cystitis-pipeline-review-h1-2017.html . The Interstitial Cystitis Companies Profiled are Allergan Plc, Aquinox Pharmaceuticals Inc, Astellas Pharma Inc, BELLUS Health Inc, Kytogenics Pharmaceuticals Inc, Lipella Pharmaceuticals Inc, Merck & Co Inc, UCB SA, Urigen Pharmaceuticals Inc, Xigen SA The Interstitial Cystitis market report features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. Key companies involved in Interstitial Cystitis (Genito Urinary System and Sex Hormones) therapeutics and enlists all their major and minor projects. Scope: The pipeline guide provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Genito Urinary System and Sex Hormones). The pipeline guide reviews pipeline therapeutics for Interstitial Cystitis (Genito Urinary System and Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.  The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Interstitial Cystitis (Genito Urinary System and Sex Hormones) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Interstitial Cystitis (Genito Urinary System and Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.  The pipeline guide reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Genito Urinary System and Sex Hormones). Reasons to buy: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Interstitial Cystitis (Genito Urinary System and Sex Hormones). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Interstitial Cystitis (Genito Urinary System and Sex Hormones) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Explore more reports on Pharmaceuticals at http://www.reportsnreports.com/market-research/pharmaceuticals/ . ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.


Browse 19 Tables and 10 Figures, 10 Companies, spread across 82 pages available at http://www.reportsnreports.com/reports/983972-interstitial-cystitis-pipeline-review-h1-2017.html . The Interstitial Cystitis Companies Profiled are Allergan Plc, Aquinox Pharmaceuticals Inc, Astellas Pharma Inc, BELLUS Health Inc, Kytogenics Pharmaceuticals Inc, Lipella Pharmaceuticals Inc, Merck & Co Inc, UCB SA, Urigen Pharmaceuticals Inc, Xigen SA The Interstitial Cystitis market report features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. Key companies involved in Interstitial Cystitis (Genito Urinary System and Sex Hormones) therapeutics and enlists all their major and minor projects. Scope: The pipeline guide provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Genito Urinary System and Sex Hormones). The pipeline guide reviews pipeline therapeutics for Interstitial Cystitis (Genito Urinary System and Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.  The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Interstitial Cystitis (Genito Urinary System and Sex Hormones) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Interstitial Cystitis (Genito Urinary System and Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.  The pipeline guide reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Genito Urinary System and Sex Hormones). Reasons to buy: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Interstitial Cystitis (Genito Urinary System and Sex Hormones). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Interstitial Cystitis (Genito Urinary System and Sex Hormones) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Explore more reports on Pharmaceuticals at http://www.reportsnreports.com/market-research/pharmaceuticals/ . ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.


Martineau E.,University of Ottawa | Martineau E.,BELLUS Health Inc. | de Guzman J.M.,BELLUS Health Inc. | Rodionova L.,BELLUS Health Inc. | And 3 more authors.
Journal of the American Society for Mass Spectrometry | Year: 2010

This paper describes an efficient and reproducible screening method for identifying low molecular weight compounds that bind to amyloid β peptides (Aβ) peptides using electrospray ionization mass spectrometry (ESI-MS). Low molecular weight compounds capable of interacting with soluble Aβ may be able to modulate/inhibit the Aβ aggregation process and serve as potential disease-modifying agents for AD. The present approach was used to rank the binding affinity of a library of compounds to Aβ1-40 peptide. The results obtained show that low molecular weight compounds bind similarly to Aβ1-42, Aβ1-40, as well as Aβ1-28 peptides and they underline the critical role of Aβ peptide charge motif in binding at physiological pH. Finally, some elements of structure-activity relationship (SAR) involved in the binding affinity of homotaurine to soluble Aβ peptides are discussed. © 2010.


Aisen P.S.,University of California at San Diego | Gauthier S.,ll Center for Studies in Aging | Ferris S.H.,New York University | Ferris S.H.,Nathan Kline Institute | And 9 more authors.
Archives of Medical Science | Year: 2011

Introduction: The aim of the study was to assess the clinical efficacy, safety, and disease-modification effects of tramiprosate (homotaurine, ALZHEMED™) in mild-to-moderate Alzheimer's disease (AD). Material and methods: Double-blind, placebo-controlled, randomized trial in 67 clinical centres across North America. Patients aged ≥ 50 years, with mild-to-moderate AD (Mini-Mental State Examination score between 16 and 26) and on stable doses of cholinesterase inhibitors, alone or with memantine. Intervention: 78-week treatment with placebo, tramiprosate 100 mg or tramiprosate 150 mg BID. Measurements: Alzheimer Disease Assessment Scale - cognitive subscale (ADAS-cog) and Clinical Dementia Rating - Sum of Boxes (CDR-SB) assessments were performed at baseline and every 13 weeks. Baseline and 78-week magnetic resonance imaging (MRI) hippocampus volume (HV) measurements were conducted in a subgroup of patients. Results: A total of 1,052 patients were enrolled and 790 (75.1%) completed the 78-week trial. Patient discontinuation and reasons for withdrawal were similar across groups. Planned analyses did not reveal statistically significant between-group differences. Lack of adequate statistical validity of the planned analysis models led to the development of revised predictive models. These adjusted models showed a trend toward a treatment effect for ADAS-cog (P = 0.098) and indicated significantly less HV loss for tramiprosate 100 mg (P = 0.035) and 150 mg (P = 0.009) compared to placebo. The incidence of adverse events was similar across treatment groups. Conclusions: The primary planned analyses did not show a significant treatment effect, but were confounded by unexplained variance. Post-hoc analyses showed a significant treatment-related reduction in HV loss. However, there was only a trend towards slowing of decline on the ADAS-cog and no slowing of decline on the CDR-SB. These results must be interpreted in consideration of the limitations of clinical and disease-modification outcome measures and their relationship, the heterogeneity of the disease and the impact of confounding demographic and clinical variables. Copyright © 2011 Termedia & Banach.


The invention relates to methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid (1,3PDS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 1,3PDS, either in vitro or in vivo. The invention also relates to sulfonate ester prodrugs of 1,3PDS as well as Gemini dimmers and oligomers of 1,3PDS for the prevention or treatment of associated diseases and conditions.


Patent
BELLUS Health Inc. | Date: 2011-09-20

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.


LONDON, UK / ACCESSWIRE / February 27, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Oncolytics Biotech, BELLUS Health, Emerald Health Therapeutics, and OrganiGram Holdings. Get all of our free research reports by signing up at: On Friday, February 24, 2017, the Toronto Exchange Composite Index was down 1.57%, finishing the day at 15,533.47. The TSX Venture Composite Index, on the other hand, closed at 836.27, down 0.38%. The Healthcare Index was also in the red, closing the day at 74.08, down 2.31%. Active Wall St. has initiated research reports on the following equities: Oncolytics Biotech Inc. (TSX: ONC), BELLUS Health Inc. (TSX: BLU), Emerald Health Therapeutics Inc. (TSX-V: EMH), and OrganiGram Holdings Inc. (TSX-V: OGI). Register with us now for your free membership and research reports at: Calgary, Canada headquartered Oncolytics Biotech Inc.'s stock fell 5.13%, to finish Friday's session at $0.37 with a total volume of 203,121 shares traded. Over the last one month and the previous three months, Oncolytics Biotech's shares have surged 37.04% and 68.18%, respectively. Shares of the Company, which focuses on the discovery and development of pharmaceutical products for the treatment of cancers, are trading above its 50-day and 200-day moving averages. See our research report on ONC.TO at: On Friday, shares in Laval, Canada-based BELLUS Health Inc. recorded a trading volume of 261,020 shares, which was higher than their three months average volume of 55,040 shares. The stock ended the day 3.85% lower at $0.25. BELLUS Health's stock has advanced 4.17% in the past three months. Shares of the Company, which together with its subsidiaries, focuses on the research and development of drugs for rare diseases, are trading below its 50-day moving average of $0.27. The complimentary research report on BLU.TO at: On Friday, shares in Victoria, Canada headquartered Emerald Health Therapeutics Inc. ended the session 1.45% lower at $1.36 with a total volume of 906,734 shares traded. Emerald Health Therapeutics' shares have surged 724.24% in the past one year. Shares of the Company, which together with its subsidiaries, produces and sells medical marijuana in Canada, are trading above its 200-day moving average. Further, the stock's 50-day moving average of $1.43 is greater than its 200-day moving average of $1.01. Register for free and access the latest research report on EMH.V at: Moncton, Canada-based OrganiGram Holdings Inc.'s stock closed the day 1.89% lower at $2.60. The stock recorded a trading volume of 811,924 shares. OrganiGram's shares have rallied 242.11% in the previous one year. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $2.71 is greater than its 200-day moving average of $2.50. Shares of the Company, which through its subsidiary, Organigram Inc., produces and sells medical marijuana in Canada, are trading at a PE ratio of 650.00. Get free access to your research report on OGI.V at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / February 27, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Oncolytics Biotech, BELLUS Health, Emerald Health Therapeutics, and OrganiGram Holdings. Get all of our free research reports by signing up at: On Friday, February 24, 2017, the Toronto Exchange Composite Index was down 1.57%, finishing the day at 15,533.47. The TSX Venture Composite Index, on the other hand, closed at 836.27, down 0.38%. The Healthcare Index was also in the red, closing the day at 74.08, down 2.31%. Active Wall St. has initiated research reports on the following equities: Oncolytics Biotech Inc. (TSX: ONC), BELLUS Health Inc. (TSX: BLU), Emerald Health Therapeutics Inc. (TSX-V: EMH), and OrganiGram Holdings Inc. (TSX-V: OGI). Register with us now for your free membership and research reports at: Calgary, Canada headquartered Oncolytics Biotech Inc.'s stock fell 5.13%, to finish Friday's session at $0.37 with a total volume of 203,121 shares traded. Over the last one month and the previous three months, Oncolytics Biotech's shares have surged 37.04% and 68.18%, respectively. Shares of the Company, which focuses on the discovery and development of pharmaceutical products for the treatment of cancers, are trading above its 50-day and 200-day moving averages. See our research report on ONC.TO at: On Friday, shares in Laval, Canada-based BELLUS Health Inc. recorded a trading volume of 261,020 shares, which was higher than their three months average volume of 55,040 shares. The stock ended the day 3.85% lower at $0.25. BELLUS Health's stock has advanced 4.17% in the past three months. Shares of the Company, which together with its subsidiaries, focuses on the research and development of drugs for rare diseases, are trading below its 50-day moving average of $0.27. The complimentary research report on BLU.TO at: On Friday, shares in Victoria, Canada headquartered Emerald Health Therapeutics Inc. ended the session 1.45% lower at $1.36 with a total volume of 906,734 shares traded. Emerald Health Therapeutics' shares have surged 724.24% in the past one year. Shares of the Company, which together with its subsidiaries, produces and sells medical marijuana in Canada, are trading above its 200-day moving average. Further, the stock's 50-day moving average of $1.43 is greater than its 200-day moving average of $1.01. Register for free and access the latest research report on EMH.V at: Moncton, Canada-based OrganiGram Holdings Inc.'s stock closed the day 1.89% lower at $2.60. The stock recorded a trading volume of 811,924 shares. OrganiGram's shares have rallied 242.11% in the previous one year. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $2.71 is greater than its 200-day moving average of $2.50. Shares of the Company, which through its subsidiary, Organigram Inc., produces and sells medical marijuana in Canada, are trading at a PE ratio of 650.00. Get free access to your research report on OGI.V at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


LONDON, UK / ACCESSWIRE / February 27, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Oncolytics Biotech, BELLUS Health, Emerald Health Therapeutics, and OrganiGram Holdings. Get all of our free research reports by signing up at: On Friday, February 24, 2017, the Toronto Exchange Composite Index was down 1.57%, finishing the day at 15,533.47. The TSX Venture Composite Index, on the other hand, closed at 836.27, down 0.38%. The Healthcare Index was also in the red, closing the day at 74.08, down 2.31%. Active Wall St. has initiated research reports on the following equities: Oncolytics Biotech Inc. (TSX: ONC), BELLUS Health Inc. (TSX: BLU), Emerald Health Therapeutics Inc. (TSX-V: EMH), and OrganiGram Holdings Inc. (TSX-V: OGI). Register with us now for your free membership and research reports at: Calgary, Canada headquartered Oncolytics Biotech Inc.'s stock fell 5.13%, to finish Friday's session at $0.37 with a total volume of 203,121 shares traded. Over the last one month and the previous three months, Oncolytics Biotech's shares have surged 37.04% and 68.18%, respectively. Shares of the Company, which focuses on the discovery and development of pharmaceutical products for the treatment of cancers, are trading above its 50-day and 200-day moving averages. See our research report on ONC.TO at: On Friday, shares in Laval, Canada-based BELLUS Health Inc. recorded a trading volume of 261,020 shares, which was higher than their three months average volume of 55,040 shares. The stock ended the day 3.85% lower at $0.25. BELLUS Health's stock has advanced 4.17% in the past three months. Shares of the Company, which together with its subsidiaries, focuses on the research and development of drugs for rare diseases, are trading below its 50-day moving average of $0.27. The complimentary research report on BLU.TO at: On Friday, shares in Victoria, Canada headquartered Emerald Health Therapeutics Inc. ended the session 1.45% lower at $1.36 with a total volume of 906,734 shares traded. Emerald Health Therapeutics' shares have surged 724.24% in the past one year. Shares of the Company, which together with its subsidiaries, produces and sells medical marijuana in Canada, are trading above its 200-day moving average. Further, the stock's 50-day moving average of $1.43 is greater than its 200-day moving average of $1.01. Register for free and access the latest research report on EMH.V at: Moncton, Canada-based OrganiGram Holdings Inc.'s stock closed the day 1.89% lower at $2.60. The stock recorded a trading volume of 811,924 shares. OrganiGram's shares have rallied 242.11% in the previous one year. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $2.71 is greater than its 200-day moving average of $2.50. Shares of the Company, which through its subsidiary, Organigram Inc., produces and sells medical marijuana in Canada, are trading at a PE ratio of 650.00. Get free access to your research report on OGI.V at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Loading BELLUS Health Inc. collaborators
Loading BELLUS Health Inc. collaborators